Skip to main content


Fig. 2 | Molecular Neurodegeneration

Fig. 2

From: Targeting tauopathy with engineered tau-degrading intrabodies

Fig. 2

Expression of tau-degrading intrabodies decreases human tau in neurons. a Representative images of primary neurons co-expressing P301S-htau and the various anti-tau intrabodies. Expression of the conventional anti-tau intrabody, intrabody-K48R or the intrabody-K63R displayed a marked decrease in h-tau protein levels relative to the AAV-control; scale bar 50 μm. b P301S-htau protein quantification by tau ELISA in primary neurons co-expressing the various intrabodies revealed a significant decrease in h-tau protein levels upon expression of each tau-degrading intrabody relative to the AAV-controls. Expression of the conventional anti-tau intrabody displayed an non-significant decrease in h-tau protein relative to the AAV-control. Results are representative of three independent experiments, all data are expressed as mean ± s.e.m. and one-way ANOVA was performed with Tukey’s Multiple Comparison. *p < 0.05

Back to article page